Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Ryght and Lucem Health partner to advance disease detection and treatment with AI technology


LAGUNA BEACH, Calif., Feb. 27, 2024 /PRNewswire/ -- Ryght, an innovator in generative AI (GenAI) technology for life science companies, today announced a partnership with Lucem Health to deploy applications that incorporate Ryght's GenAI capabilities into the Lucem Health platform. The collaboration aims to enable Lucem Health to add GenAI to its AI SolutionOps platform and use it to enhance the company's early disease detection and treatment acceleration solutions.

Lucem Health and Ryght will leverage specialized access to Ryght's advanced GenAI technology, which utilizes various large language models (LLMs) fine-tuned for the sector. The technology will enable Lucem Health to develop new insights from longitudinal patient records, including a more robust understanding of the journeys and experiences of patients living with diseases.

"Lucem Health is a leader in delivering early disease detection and treatment acceleration solutions to healthcare providers, and we are looking forward to our collaboration," said Simon Arkell, CEO of Ryght. "Lucem Health's AI SolutionOps platform already provides a robust set of capabilities to bring the power of clinical AI from the bench to the bedside. We look forward to helping the Lucem Health team enhance its platform and solutions by incorporating our innovative copilots and applications. The collaboration between Lucem Health and Ryght will deliver significant benefits, such as improved patient outcomes, reduced costs, enhanced quality of care, and increased patient satisfaction."

"We are excited to partner with Ryght and leverage their GenAI platform and expertise," said Sean Cassidy, CEO of Lucem Health. "Ryght's cutting-edge technology aligns perfectly with our vision of using the power and potential of AI to transform healthcare data into novel, actionable insights that help clinicians practice more proactive care that delivers better patient outcomes."

RSVP for Ryght's upcoming LinkedIn Live discussion on Thursday, Feb. 29, 2024, to learn more about how GenAI is reshaping the landscape of clinical development. Interested individuals can request access to a free version of Ryght currently available in beta at www.ryght.ai.

About Ryght:

Ryght is a privately held healthcare technology company based in Laguna Beach, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Ryght platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare and life sciences professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry.

For more information, please visit the company's website at www.ryght.ai. Follow the company on LinkedIn.

About Lucem Health:

Lucem Health helps healthcare providers accelerate disease detection and treatment using practical, responsible AI?so they can improve patients' lives and increase the clinical and financial yield from today's scarce care delivery resources. Learn more at www.lucemhealth.com.

Media Contacts:

For Ryght:

Brian Dranka
VP, Product & Marketing
[email protected]

For Lucem Health:

Oscar Eclov-Reher
Director, Marketing
[email protected]

SOURCE Ryght


These press releases may also interest you

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...

17 mai 2024
The Honourable Seamus O'Regan Jr., Minister of Labour and Seniors, on behalf of the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Tom Osborne, Newfoundland and Labrador's Minister of Health and Community Services will make...



News published on and distributed by: